Lymphoma References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Hansmann ML, Kuppers R. Pathology and "molecular histology" of Hodgkin's disease and the border to non-Hodgkin's lymphomas. Baillieres Clin Haematol . 1996 Sep;9(3):459-77.
  2. Lister TA, Crowther D et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol . 1989 Nov;7(11):1630-6.
  3. Jose BO, Koerner P et al. Hodgkin's lymphoma in adults--clinical features. J Ky Med Assoc . 2005 Jan;103(1):15-7.
  4. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol . 1999 Feb;12(2):159-75.
  5. Kuppers R, Schwering I et al. Biology of Hodgkin's lymphoma. Ann Oncol . 2002;13 Suppl 1:11-8.
  6. Brauninger A, Hansmann ML et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med . 1999 Apr 22;340(16):1239-47.
  7. Coffey J, Hodgson DC et al. Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging . 2003 Jun;30 Suppl 1:S28-S36.
  8. Jimenez-Zepeda VH, Jimenez-Zepeda RJ. [Non-Hodgkin's lymphoma: biologic classification, diagnosis and treatment]. Gac Med Mex . 1998 Jul;134(4):443-63.
  9. Groves FD, Linet MS et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst . 2000 Aug 2;92(15):1240-51.
  10. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene . 2004 Aug 23;23(38):6524-34.
  11. Hauke RJ, Armitage JO. A new approach to non-Hodgkin's lymphoma. Intern Med . 2000 Mar;39(3):197-208.
  12. Mohammad RM, Al-Katib A et al. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther . 2003 Dec;2(12):1361-8.
  13. Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol . 2000 Sep;12(5):383-94.
  14. Cartwright RA, Gurney KA et al. Sex ratios and the risks of haematological malignancies. Br J Haematol . 2002 Sep;118(4):1071-7.
  15. Glaser SL. Black-white differences in Hodgkin's disease incidence in the United States by age, sex, histology subtype and time. Int J Epidemiol . 1991 Mar;20(1):68-75.
  16. Pasqualucci L, Bereschenko O et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma . 2003;44 Suppl 3:S5-12.
  17. Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol. 2004 Nov;16(6):581-5.
  18. Jarrett RF. Risk factors for Hodgkin’s lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44 Suppl 3:S27-32.
  19. Krueger GR, Guenther A et al. Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6. In Vivo . 1994 Jul;8(4):501-16.
  20. Danese C, Angrisani L et al. [A five year follow-up of a Primary Effusion Lymphoma HHV-8 related in an HIV-negative elderly patient]. Clin Ter . 2004 Nov;155(11-12):543-6.
  21. Muller AM, Ihorst G et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol . 2005 Jan;84(1):1-12.
  22. Lim ST, Levine AM. Non-AIDS-defining cancers and HIV infection. Curr Infect Dis Rep . 2005 May;7(3):227-34.
  23. Thompson LD, Fisher SI et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol . 2004 May;121(5):727-38.
  24. Zhang S, Hunter DJ et al. Dietary fat and protein in relation to risk of non-Hodgkin's lymphoma among women. J Natl Cancer Inst . 1999 Oct 20;91(20):1751-8.
  25. Zhang SM, Hunter DJ et al. Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin's lymphoma among women. Cancer Epidemiol Biomarkers Prev . 2000 May;9(5):477-85.
  26. Calder PC, Yaqoob P et al. Fatty acids and lymphocyte functions. Br J Nutr . 2002 Jan;87 Suppl 1:S31-S48.
  27. Jones DE. Fat is an immuno-regulatory issue. Hepatology . 2005 Oct;42(4):755-8.
  28. Plat J, Mensink RP. Food components and immune function. Curr Opin Lipidol . 2005 Feb;16(1):31-7.
  29. Chang ET, Smedby KE et al. Dietary factors and risk of non-hodgkin lymphoma in men and women. Cancer Epidemiol Biomarkers Prev . 2005 Feb;14(2):512-20.
  30. Chiu BC, Cerhan JR et al. Diet and risk of non-Hodgkin lymphoma in older women. JAMA . 1996 May 1;275(17):1315-21.
  31. De SE, Fierro L et al. Tobacco, alcohol, diet and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay. Leuk Res . 1998 May;22(5):445-52.
  32. Gaisbauer M, Langosch A. [Raw food and immunity]. Fortschr Med . 1990 Jun 10;108(17):338-40.
  33. Rossing N. [Raw food against cancer. A report from a study done by the Society for Alternative Medicine]. Ugeskr Laeger . 1988 Mar 7;150(10):613-5.
  34. van LOGHEM JJ. [Raw food to cure cancer.]. Ned Tijdschr Geneeskd . 1951 Feb 10;95(6):482-3.
  35. Zheng T, Holford TR et al. Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol . 2004 Mar 1;159(5):454-66.
  36. Cerhan JR. New epidemiologic leads in the etiology of non-Hodgkin lymphoma in the elderly: the role of blood transfusion and diet. Biomed Pharmacother . 1997a;51(5):200-7.
  37. Vamvakas EC. Allogeneic blood transfusion as a risk factor for the subsequent development of non-Hodgkin's lymphoma. Transfus Med Rev . 2000 Jul;14(3):258-68.
  38. Cerhan JR, Wallace RB et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst . 1997b Feb 19;89(4):314-8.
  39. Natazuka T, Manabe Y et al. Association between non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. BMJ . 1994 Nov 12;309(6964):1269.
  40. Jackson RM, Rice DH. Acute bacterial sinusitis and diabetes mellitus. Otolaryngol Head Neck Surg . 1987 Nov;97(5):469-73.
  41. Kohn LD, Wallace B et al. Is type 2 diabetes an autoimmune-inflammatory disorder of the innate immune system? Endocrinology . 2005 Oct;146(10):4189-91.
  42. Catassi C, Fabiani E et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA . 2002 Mar 20;287(11):1413-9.
  43. Smedby KE, Akerman M et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut . 2005 Jan;54(1):54-9.
  44. Sonet A, Theate I et al. Clinical and pathological features of 14 non-Hodgkin's lymphomas associated with coeliac disease. Acta Clin Belg . 2004 May;59(3):143-51.
  45. Fiorilli M, Mecucci C et al. HCV-associated lymphomas. Rev Clin Exp Hematol . 2003 Dec;7(4):406-23.
  46. Vallisa D, Bernuzzi P et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol . 2005 Jan 20;23(3):468-73.
  47. Seve P, Renaudier P et al. Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France. Eur J Gastroenterol Hepatol . 2004 Nov;16(12):1361-5.
  48. Noronha V, Shafi NQ et al. Primary non-Hodgkin's lymphoma of the liver. Crit Rev Oncol Hematol . 2005 Mar;53(3):199-207.
  49. Giannoulis E, Economopoulos T et al. The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic Cooperative Oncology Group Study. Acta Haematol . 2004;112(4):189-93.
  50. Morgensztern D, Rosado M et al. Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature. Leuk Lymphoma . 2004 Dec;45(12):2459-64.
  51. Franco M, Rugge M et al. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori: scratch and win. Scand J Gastroenterol . 2005 Jan;40(1):115-9.
  52. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Annu Rev Med . 1998;49:289-99.
  53. Irwin D, Kaplan L. Clinical aspects of HIV-related lymphoma. Curr Opin Oncol . 1993 Sep;5(5):852-60.
  54. Kaplan LD. AIDS-associated lymphoma. Baillieres Clin Haematol . 1990 Jan;3(1):139-51.
  55. Tulpule A, Levine A. AIDS-related lymphoma. Blood Rev . 1999 Sep;13(3):147-50.
  56. Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol . 2005 Mar;78(3):232-9.
  57. Quintana PJ, Delfino RJ et al. Adipose tissue levels of organochlorine pesticides and polychlorinated biphenyls and risk of non-Hodgkin's lymphoma. Environ Health Perspect . 2004 Jun;112(8):854-61.
  58. Waddell BL, Zahm SH et al. Agricultural use of organophosphate pesticides and the risk of non-Hodgkin's lymphoma among male farmers (United States). Cancer Causes Control . 2001 Aug;12(6):509-17.
  59. Weisenburger DD. Environmental epidemiology of non-Hodgkin's lymphoma in eastern Nebraska. Am J Ind Med . 1990;18(3):303-5.
  60. Lee WJ, Cantor KP et al. Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. Int J Cancer . 2004 Aug 20;111(2):298-302.
  61. Floret N, Mauny F et al. Dioxin emissions from a solid waste incinerator and risk of non-Hodgkin lymphoma. Epidemiology . 2003 Jul;14(4):392-8.
  62. Ward MH, Mark SD et al. Drinking water nitrate and the risk of non-Hodgkin's lymphoma. Epidemiology . 1996 Sep;7(5):465-71.
  63. Freedman DM, Cantor KP et al. A case-control study of nitrate in drinking water and non-Hodgkin's lymphoma in Minnesota. Arch Environ Health . 2000 Sep;55(5):326-9.
  64. Cerhan JR, Vachon CM et al. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev . 2002 Nov;11(11):1466-71.
  65. Kato I, Koenig KL et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control . 2002 Dec;13(10):965-74.
  66. Kato I, Koenig KL et al. History of antibiotic use and risk of non-Hodgkin's lymphoma (NHL). Int J Cancer . 2003 Oct 20;107(1):99-105.
  67. Cerhan JR, Anderson KE et al. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer . 2003 Sep 20;106(5):784-8.
  68. Canellos GP. Lymphoma: present and future challenges. Semin Hematol . 2004 Oct;41(4 Suppl 7):26-31.
  69. Escalon MP, Liu NS et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer . 2005 May 15;103(10):2091-8.
  70. Younes A. New treatment strategies for aggressive lymphoma. Semin Oncol . 2004 Dec;31(6 Suppl 15):10-3.
  71. Rigacci L, Carrai V et al. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study. Cancer . 2005 Mar 1;103(5):970-7.
  72. Mukai HY, Okoshi Y et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol . 2003 Jun;70(6):413-6.
  73. Lavoie JC, Connors JM et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood . 2005 May 3.
  74. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy . 2000 Jul;20(7 Pt 2):104S-11S.
  75. Holmes FF, Wilson J et al. Biology of cancer and aging. Cancer . 1991 Dec 1;68(11 Suppl):2525-6.
  76. Chatta GS, Dale DC. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging . 1996 Jul;9(1):37-47.
  77. Tajima M. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10]. Gan No Rinsho . 1984 Jul;30(9 Suppl):1211-6.
  78. Tsubaki K, Horiuchi A et al. [Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents]. Gan To Kagaku Ryoho . 1984 Jul;11(7):1420-7.
  79. Iarussi D, Auricchio U et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med . 1994;15 Suppl:s207-s212.
  80. Wang SQ. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases]. Zhonghua Zhong Liu Za Zhi . 1991 Jan;13(1):71-3.
  81. Maloney DG. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. Semin Oncol . 2005 Feb;32(1 Suppl 1):S19-S26.
  82. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs . 2003;63(8):803-43.
  83. Nakai S, Masaki T et al. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): A case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma. Oncol Rep . 2005 Jun;13(6):1065-8.
  84. Feugier P, Van HA et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol . 2005 May 2.
  85. Jetsrisuparb A, Wiangnon S et al. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's Lymphoma. J Pediatr Hematol Oncol . 2005 Apr;27(4):223-6.
  86. Lenz G, Dreyling M et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol . 2005 Mar 20;23(9):1984-92.
  87. DeNardo GL. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Semin Oncol . 2005 Feb;32(1 Suppl 1):S27-S35.
  88. Dillman RO. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Curr Hematol Rep . 2003 Jan;2(1):30-7.
  89. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol . 2003 Dec;30(6 Suppl 17):1-5.
  90. Grillo-Lopez AJ. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Semin Oncol . 2005 Feb;32(1 Suppl 1):S44-S49.
  91. Lewington V. Development of 131I-tositumomab. Semin Oncol . 2005 Feb;32(1 Suppl 1):S50-S56.
  92. Wiseman GA, Witzig TE. Yttrium-90 (90Y ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's Lymphoma. Cancer Biother Radiopharm . 2005 Apr;20(2):185-8.
  93. Riley MB, Gordon LI. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol Nurs. 2004 Feb;20(1 Suppl 1):8-13.
  94. Macklis RM. Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin's Lymphoma. Semin Radiat Oncol. 2007 Jul;17(3):176-83.
  95. Witzig TE, Molina A, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007 May 1;109(9):1804-10.
  96. Witzig TE, Gordon LI, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63.
  97. Han SS, Chung ST et al. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol . 1999 Nov;93(2):152-61.
  98. Ranjan D, Johnston TD et al. Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. J Surg Res . 1999 Nov;87(1):1-5.
  99. Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. Zhonghua Zhong Liu Za Zhi . 2002b Jul;24(4):348-52.
  100. Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. Zhonghua Zhong Liu Za Zhi . 2002c Jul;24(4):348-52.
  101. Dulak J. Nutraceuticals as anti-angiogenic agents: hopes and reality. J Physiol Pharmacol . 2005 Mar;56 Suppl 1:51-69.
  102. Gescher A. Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents? J Chemother . 2004 Nov;16 Suppl 4:3-6.
  103. Baxa DM, Yoshimura FK. Genistein reduces NF-kappa B in T lymphoma cells via a caspase-mediated cleavage of I kappa B alpha. Biochem Pharmacol . 2003 Sep 15;66(6):1009-18.
  104. Buckley AR, Buckley DJ et al. Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. Mol Cell Endocrinol . 1993 Dec;98(1):17-25.
  105. Kempf W, Kettelhack N et al. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am . 2003 Dec;17(6):1405-19.
  106. Mahrle G, Thiele B. Retinoids in cutaneous T cell lymphomas. Dermatologica . 1987;175 Suppl 1:145-50.
  107. Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther . 2003;16(4):322-30.
  108. Mathiasen IS, Colston KW et al. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol . 1993 Sep;46(3):365-71.
  109. Bertolini F, Fusetti L et al. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia . 2000 Aug;14(8):1477-82.
  110. Katsuno Y, Koyama Y et al. Apoptosis-inducing activity of a driselase digest fraction of green tea residue. Biosci Biotechnol Biochem . 2001 Jan;65(1):198-201.
  111. Chen Q, Espey MG et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A . 2005 Sep 20;102(38):13604-9.
  112. Nagy B, Mucsi I et al. Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. In Vivo . 2003 May;17(3):289-92.
  113. Prasad SB, Giri A et al. Use of subtherapeutical dose of cisplatin and vitamin C against murine Dalton's lymphoma. Pol J Pharmacol Pharm . 1992 Jul;44(4):383-91.
  114. Ashfaq MK, Zuberi HS et al. Vitamin E and beta-carotene affect natural killer cell function. Int J Food Sci Nutr . 2000;51 Suppl:S13-S20.
  115. Dalen H, Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer . 2003b Jan 13;88(1):153-8.
  116. Dasgupta J, Sanyal U et al. Vitamin E--its status and role in leukemia and lymphoma. Neoplasma . 1993;40(4):235-40.
  117. Dalen H, Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer . 2003a Jan 13;88(1):153-8.
  118. Bao X, Liu C, Fang J, Li X. Structural and immunological studies of a major polysaccharide from spores of Ganoderma lucidum (Fr.) Karst. Carbohydr Res. 2001 May 8;332(1):67-74.
  119. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011;39(1):15-27.
  120. Yeh CH, Chen HC, Yang JJ, Chuang WI, Sheu F. Polysaccharides PS-G and protein LZ-8 from Reishi (Ganoderma lucidum) exhibit diverse functions in regulating murine macrophages and T lymphocytes. J Agric Food Chem. 2010 Aug 11;58(15):8535-44.
  121. Cao LZ, Lin ZB. Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett. 2002 Oct 1;83(3):163-9.
  122. Lai CY, Hung JT, Lin HH, et al. Immunomodulatory and adjuvant activities of a polysaccharide extract of Ganoderma lucidum in vivo and in vitro. Vaccine. 2010 Jul 12;28(31):4945-54.
  123. Jan RH, Lin TY, Hsu YC, et al. Immuno-modulatory activity of Ganoderma lucidum-derived polysacharide on human monocytoid dendritic cells pulsed with Der p 1 allergen. BMC Immunol. 2011;12:31.
  124. Ji Z, Tang Q, Zhang J, Yang Y, Liu Y, Pan YJ. Immunomodulation of bone marrow macrophages by GLIS, a proteoglycan fraction from Lingzhi or Reishi medicinal mushroom Ganoderma lucidium (W.Curt.:Fr.) P. Karst. Int J Med Mushrooms.2011;13(5):441-8.
  125. Chan WK, Lam DT, Law HK, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Altern Complement Med. 2005 Dec;11(6):1047-57.
  126. Chu CL, Chen Dz C, Lin CC. A novel adjuvant Ling Zhi-8 for cancer DNA vaccines. Hum Vaccin. 2011 Nov;7(11):1161-4.
  127. Lin CC, Yu YL, Shih CC, et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunol Immunother. 2011 Jul;60(7): 1019-27.
  128. Zhu XL, Liu JH, Li WD, Lin ZB. Promotion of myelopoiesis in myelosuppressed mice by Ganoderma lucidum polysaccharides. Front Pharmacol. 2012;3:20.
  129. Zhu XL, Chen AF, Lin ZB. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol. 2007 May 4;111(2):219-26.
  130. Wang PY, Zhu XL, Lin ZB. Antitumor and immunomodulatory effects of polysaccharides from broken-spore of Ganoderma lucidum. Front Pharmacol. 2012;3:135.
  131. Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ. Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int Immunopharmacol. 2008 Aug;8(8):1124-33.
  132. Wang SY, Hsu ML, Hsu HC, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997 Mar 17;70(6):699-705.
  133. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000 Jul;7(7):715-29.
  134. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-15.
  135. Muller CI, Kumagai T, O’Kelly J, Seeram NP, Heber D, Koeffler HP. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res. 2006 Jul;30(7):841-8.
  136. Lu H, Uesaka T, Katoh O, Kyo E, Watanabe H. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep. 2001 Nov- Dec;8(6):1341-5.
  137. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. Prevention of development of N,N’-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med. 2002 Feb;9(2):113-7.
  138. Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010 Mar;59(1):1-6.
  139. Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharm. 2011 Sep 1;61(3):335-42.
  140. Bruno R, Ghisolfi L et al. Wine and tumors: study of resveratrol. Drugs Exp Clin Res . 2003;29(5-6):257-61.
  141. Park JW, Choi YJ et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett . 2001 Feb 10;163(1):43-9.
  142. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther . 2004 Jan;3(1):71-84.
  143. Miyoshi N, Nakamura Y et al. Dietary ginger constituents, galanals A and B, are potent apoptosis inducers in Human T lymphoma Jurkat cells. Cancer Lett . 2003 Sep 25;199(2):113-9.
  144. Heimli H, Finstad HS et al. Necrosis and apoptosis in lymphoma cell lines exposed to eicosapentaenoic acid and antioxidants. Lipids . 2001 Jun;36(6):613-21.
  145. Heimli H, Giske C et al. Eicosapentaenoic acid promotes apoptosis in Ramos cells via activation of caspase-3 and -9. Lipids . 2002 Aug;37(8):797-802.
  146. Heimli H, Hollung K et al. Eicosapentaenoic acid-induced apoptosis depends on acyl CoA-synthetase. Lipids . 2003 Mar;38(3):263-8.
  147. Ogilvie GK, Fettman MJ et al. Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Cancer . 2000 Apr 15;88(8):1916-28.
  148. Arditti FD, Rabinkov A et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. Mol Cancer Ther . 2005 Feb;4(2):325-31.
  149. Scharfenberg K, Wagner R et al. The cytotoxic effect of ajoene, a natural product from garlic, investigated with different cell lines. Cancer Lett . 1990 Sep;53(2-3):103-8.
  150. Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. Zhonghua Zhong Liu Za Zhi . 2002d Jul;24(4):348-52.
  151. Wu Y, Chen Y et al. Anticancer activities of curcumin on human Burkitt's lymphoma. Zhonghua Zhong Liu Za Zhi . 2002a Jul;24(4):348-52.
  152. Pedersen LM, Klausen TW et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol . 2005 Apr 15.
  153. Litam P, Swan F et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med . 1991 May 15;114(10):855-60.
  154. Schneider RJ, Seibert K et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer . 1980 Jul 1;46(1):139-43.
  155. Martin S, Fischer C et al. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. Eur J Haematol . 2005 Apr;74(4):282-92.
  156. Lagman R, Walsh D. Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia. Support Care Cancer . 2003 Apr;11(4):232-5.
  157. Anderson GD, Rosito G et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol . 2003 Jun;43(6):643-8.
  158. Kakizoe T. Chemoprevention of cancer--focusing on clinical trials. Jpn J Clin Oncol . 2003 Sep;33(9):421-42.
  159. Meyskens FL, Jr., Kopecky KJ et al. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res . 1995 Sep;19(9):605-12.
  160. Mellibovsky L, Diez A et al. Long-standing remission after 25-OH D3 treatment in a case of chronic myelomonocytic leukaemia. Br J Haematol . 1993 Dec;85(4):811-2.
  161. Laurie SA, Miller VA et al. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol . 2005 Jan;55(1):33-8.
  162. Pisters KM, Newman RA et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol . 2001 Mar 15;19(6):1830-8.
  163. Walle T, Hsieh F et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos . 2004 Dec;32(12):1377-82.
  164. Betz O, Kranke P et al. [Is ginger a clinically relevant antiemetic? A systematic review of randomized controlled trials]. Forsch Komplementarmed Klass Naturheilkd . 2005 Feb;12(1):14-23.
  165. Buckley R, Shewring B et al. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr . 2004 Sep;92(3):477-83.